Equibles does not estimate personal net worth.
Get an email with a short summary when Ligand Pharmaceuticals Inc publishes a filing, an earnings call transcript or a press release.
Get LGND alertsTavo Espinoza is recorded as CFO at Ligand Pharmaceuticals Inc (LGND). The newest filing on record that lists Tavo Espinoza as CFO at Ligand Pharmaceuticals Inc (LGND) is dated April 21, 2026. The proxy statement of Ligand Pharmaceuticals Inc reports total compensation of $4,382,148 for Tavo Espinoza in fiscal 2025, including a base salary of $522,825. Disclosed compensation is on record for 4 fiscal years. Tavo Espinoza has spoken on 13 earnings calls across 1 company, most recently for Ligand Pharmaceuticals Inc on October 29, 2026. Ligand Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Ligand Pharmaceuticals Inc includes Todd C. Davis (CEO and Board Member), Jason Haas (Board Member), Jason M. Aryeh (Board Member) and 7 others.
“Before I get into the numbers, there is one change I want to share with you. Starting this quarter, we're reporting earlier than we have in the past, and we plan to keep that schedule through 2027.”
“As you've highlighted, we're entering a new chapter for Ligand. The business is performing exceptionally well. We've significantly expanded our royalty portfolio through the Zoma acquisition, and we further strengthened an already exceptional balance sheet.”
“Yeah, you know, we had Phil Spari for FSGS on a risk-adjusted basis included in our model coming into the year. And we talked about that at Investor Day. And so now that obviously it's approved, it's de-risked.”
“Before getting into the broader overview, I want to start with the deconsolidation of PELTHOS since it provides an important context for this quarter's results.”
“I'm pleased to report a strong start to the year, with the first quarter results that position as well to achieve both our 2025 financial guidance and our longer-term growth objectives.”
Start not stated–present
Last confirmed April 21, 2026
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Ligand Pharmaceuticals Inc (LGND) | Chief Financial Officer | $522,825 | $4,382,148 |
| 2024 | Ligand Pharmaceuticals Inc (LGND) | Chief Financial Officer | $469,550 | $3,298,556 |
| 2023 | Ligand Pharmaceuticals Inc (LGND) | Chief Financial Officer | $433,005 | $2,450,631 |
| 2022 | Ligand Pharmaceuticals Inc (LGND) | Chief Financial Officer | $330,097 | $3,272,252 |
